Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479133 | 0.94 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5385802 | 0.91 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5369525 | 0.91 | AGPAT2 (0.83) | AGPAT2 | |
| SCHEMBL5375395 | 0.90 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5371435 | 0.86 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL14439013 | 0.81 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL9911730 | 0.81 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5373033 | 0.78 | AGPAT2 (0.82) | AGPAT2 | |
| SCHEMBL5379798 | 0.77 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL13880223 | 0.76 | AGPAT2 (0.89) | AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875781-B2 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-04-05 | — | — | US | claimed |
| US-9622993-B2 | Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9622993-B2 | Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170027893-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170027893-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015157242-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050182102-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6875781-B2 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040198728-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198728-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 23/4885 |
| US-20170027893-A1 | THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF | BRAF, PLAAT3, PLAAT2 | AGPAT2 91/4885 |
| US-20070178134-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885 |
| US-20050182102-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.